William Blair analyst Tim Lugo reiterated an Outperform rating on VistaGen Therapeutics (NASDAQ: VTGN) following the company's most recent quarterly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE